ClinHope Opens Hong Kong Branch Expanding into Asia-Pacific Market

TAIPEI, Sept. 3, 2026 /CourierPR/ -- ClinHope, a biotech and pharmaceutical services company, has officially opened its Hong Kong branch, marking a significant expansion into the Asia-Pacific market. Following successful operations in Taiwan and the United States, this latest move underscores ClinHope’s commitment to global growth and enhanced service delivery.

Based in Hong Kong, a highly internationalized environment and strategic hub for connecting Asia with global markets, ClinHope aims to leverage its new base to expand regional markets and foster international collaboration. The company plans to integrate resources from Taiwan, the United States, and Hong Kong to offer more comprehensive cross-regional services to its clients.

Ms. Abby Chang, CEO of ClinHope, emphasized the importance of the Hong Kong branch. "The establishment of our Hong Kong branch is a critical milestone in our globalization journey," she said. "We are committed to expanding our Asia-Pacific and global collaboration networks, combining local expertise with an international perspective to provide top-tier services in clinical research, regulatory affairs, and quality management."

ClinHope specializes in providing professional services for the biotech, pharmaceutical, and medical device industries. Its services include clinical trials, regulatory affairs, quality management, and related projects and consulting. The company is dedicated to helping its clients meet diverse professional and regulatory requirements across different markets.

With operations now established in Taiwan, the United States, and Hong Kong, ClinHope continues to expand its global collaboration network. By integrating cross-regional teams, expertise, and local market experience, the company aims to become a trusted international partner for its clients in the biotech, pharmaceutical, and medical device sectors.

Through its Hong Kong branch, ClinHope is well-positioned to support clients in navigating the complex regulatory landscapes and clinical research requirements of the Asia-Pacific region. The company’s dedication to connecting Asian and global markets and fostering new international growth opportunities will continue to drive its success in the coming years.